- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03648931
Microbicide/PrEP Acceptability Among Mothers and Male Partners in Africa (MAMMA)
Qualitative Assessment of Acceptability of Vaginal Ring (VR) and Oral Pre-exposure Prophylaxis (PrEP) Use During Pregnancy and Breastfeeding
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
MTN-041 is an exploratory study primarily designed to identify individual, interpersonal, social and cultural factors that may affect potential uptake of two safe and effective HIV prevention products, the monthly DPV VR and daily oral PrEP, in a vulnerable yet seldom-studied population, pregnant and breastfeeding women. MTN-041 will utilize FGDs and IDIs to elicit community and health professional perceptions about vaginal practices, sexual activity, use of medicines, and HIV risk during pregnancy or breastfeeding, including how these perceptions may affect pregnant and breastfeeding women's acceptability of using intravaginal products and oral medications like the DPV VR and Truvada oral tablet.
The MTN-041 study population will consist of HIV-uninfected women 18-40 years old who are currently or were recently (within two years) pregnant or breastfeeding, men aged 18 years or older whose partners are currently or were recently (within two years) pregnant or breastfeeding, grandmothers whose daughters or daughters-in-law are currently or were recently (within two years) pregnant or breastfeeding, and key informants (KIs), which include: health care professionals (HCPs), traditional birth attendants (TBAs), providers of family planning, antenatal, and traditional health services to women, providers of other social services to women, and community leaders.
Up to 60 men and women will be selected at each site for participation in this study, for a maximum total of 240 study participants. This includes up to 50 FGD participants (currently or recently pregnant or breastfeeding women, male partners of women who are currently or were recently pregnant or breastfeeding, and grandmothers with currently or recently pregnant or breastfeeding daughters/daughters-in-law) and up to 10 KIs selected at each site, for a maximum total of 200 FGD participants and 40 KIs enrolled across all sites.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Johannesburg, Jižní Afrika
- Wits Reproductive Health and HIV Institute (WRHI) Clinical Research Site
-
-
-
-
-
Blantyre, Malawi
- Blantyre Clinical Research Site
-
-
-
-
-
Kampala, Uganda
- Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration Clinical Research Site
-
-
-
-
-
Harare, Zimbabwe
- Zengeza Clinical Research Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Able and willing to provide written informed consent in one of the study languages.
Able and willing to complete the required study procedures.
For currently or recently pregnant or breastfeeding women:
- Between the ages of 18 to 40 years old (inclusive) at Enrolment, verified per site standard operating procedures (SOPs).
Currently or recently (within two years) pregnant or breastfeeding (by self-report).
For male partners:
- Aged 18 years or older at Enrolment, verified per site SOPs.
Identifies as a primary sexual partner of a woman who is currently or was recently (within two years) pregnant or breastfeeding.
For grandmothers:
- Aged 18 years or older at Enrolment, verified per site SOPs.
Identifies as the maternal or paternal grandmother of a daughter or daughter-in-law who is currently or was recently (within two years) pregnant or breastfeeding.
Note: The term "daughter-in-law" includes women who are/were not married to their male partner during or after pregnancy.
For service provider KIs:
- Aged 18 years or older at Enrolment, verified per site SOPs.
- Currently working as a clinician (e.g., obstetrician, nurse, pharmacist, etc.), traditional care provider (e.g., TBA, healer, midwife, etc.), social service provider (e.g., social worker, family planning counselor, etc.) or community health worker in one of the study countries, verified per site SOPs.
Experienced in providing services to pregnant and/or breastfeeding women.
For community leader KIs:
- Aged 18 years or older at Enrolment, verified per site SOPs.
- Currently acting in a community leadership role (e.g., local chief, religious leader, etc.).
Exclusion Criteria:
- Has any condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
- For currently or recently pregnant or breastfeeding women: known HIV-positive status, verified per recent health record (e.g., health passport, ante-natal book, HIV test card, or similar document) or by self-report if health record(s) not available.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
---|---|
Pregnant or Breastfeeding Women
No actual intervention is planned.
A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
|
No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:
|
Male Partners
No actual intervention is planned.
A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
|
No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:
|
Grandmothers
No actual intervention is planned.
A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
|
No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:
|
Key Informants
No actual intervention is planned.
A single in-depth interview (IDI) will be conducted to assess study outcome measures.
|
No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Acceptability of VR during pregnancy and breastfeeding, including willingness to use the VR or support its use
Časové okno: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Acceptability of oral PrEP during pregnancy and breastfeeding, including willingness to use oral PrEP or support its use
Časové okno: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Product preferences during pregnancy and breastfeeding
Časové okno: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Sexual activity and contraceptive use during pregnancy and breastfeeding
Časové okno: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Perceptions of HIV risk during pregnancy and breastfeeding
Časové okno: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Community beliefs and practices related to pregnancy and breastfeeding, including use of oral medications and intravaginal products
Časové okno: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Ariane van der Straten, PhD, MPH, Women's Global Health Imperative Program, RTI International
Publikace a užitečné odkazy
Obecné publikace
- van der Straten A, Ryan JH, Reddy K, Etima J, Taulo F, Mutero P, Taylor J, Piper J, Musara P; MTN-041/MAMMA Study Team. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. J Int AIDS Soc. 2020 Jun;23(6):e25536. doi: 10.1002/jia2.25536.
- Flax VL, Hawley I, Ryan J, Chitukuta M, Mathebula F, Nakalega R, Seyama L, Taulo F, van der Straten A; MTN-041/MAMMA Study Team. After their wives have delivered, a lot of men like going out: Perceptions of HIV transmission risk and support for HIV prevention methods during breastfeeding in sub-Saharan Africa. Matern Child Nutr. 2021 Apr;17(2):e13120. doi: 10.1111/mcn.13120. Epub 2020 Dec 15.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- MTN-041
- UM1AI068633 (Grant/smlouva NIH USA)
- UM1AI068615 (Grant/smlouva NIH USA)
- UM1AI106707 (Grant/smlouva NIH USA)
- 38161 (Jiný identifikátor: DAIDS)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Prevence HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthNáborHIV | Testování HIV | HIV vazba na péči | Léčba HIVSpojené státy
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement a další spolupracovníciNeznámýHIV | Děti neinfikované HIV | Děti vystavené HIVKamerun
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationDokončenoPartnerské HIV testování | Poradenství pro pár HIV | Párová komunikace | Výskyt HIVKamerun, Dominikánská republika, Gruzie, Indie
-
University of MinnesotaStaženoHIV infekce | HIV/AIDS | Hiv | AIDS | Problém AIDS/Hiv | AIDS a infekceSpojené státy
-
Erasmus Medical CenterZatím nenabírámeHIV infekce | Hiv | HIV-1-infekce | HIV I infekceHolandsko
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... a další spolupracovníciNábor
-
Hospital Clinic of BarcelonaDokončenoInhibitory integrázy, HIV; HIV PROTEASE INHIBŠpanělsko
-
University of Maryland, BaltimoreStaženoHiv | Transplantace ledvin | Zásobník HIV | CCR5Spojené státy
-
National Taiwan UniversityNáborHiv | Testování HIVTchaj-wan
-
Helios SaludViiV HealthcareNeznámýHiv | HIV-1-infekceArgentina
Klinické studie na Focus Group Discussion (FGD)
-
University of OxfordShoklo Malaria Research UnitDokončenoPředčasný porod | Předčasně narozené dítěThajsko